Andrew Satlin, MD

Articles by Andrew Satlin, MD

Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease

July 23rd 2018

Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.

Latest Updated Articles

Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease
Published: July 23rd 2018 | Updated:

Andrew Satlin, MD

Articles by Andrew Satlin, MD

Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer Disease

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis

FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease

NDA Accepted for Narcolepsy Oxybate TRN-257, Gene Therapy ETX101 Early Promise in Dravet, Bexicaserin's Impact on Developmental Encephalopathies